In this study, we explored the possible therapeutic benefit of a small molecule benzamide dual histone deacetylase (HDAC) Class I and lysine-specific histone demethylase 1A (LSD1) inhibitor, 4SC-202 (Domatinostat), on tumor burden and metastasis in a highly metastatic TNBC murine model (4T1). This evidence concerns the gene KDM1A and neoplasm.